PDLI insider filings

PDL BIOPHARMA, INC. — 25 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-02-03. Screen PDLI transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for PDLI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — PDL BIOPHARMA, INC.

FiledFormInsiderReported transactionsSource
2021-02-034Silver Point Capital L.P. — 10% owner
O'Shea Robert J — 10% owner
MULE EDWARD A — 10% owner
Purchase (P): 187,061 @ $2.05EDGAR
2021-01-044Silver Point Capital L.P. — 10% owner
O'Shea Robert J — 10% owner
MULE EDWARD A — 10% owner
Purchase (P): 6,325,213 @ $2.50EDGAR
2020-12-314GRYSKA DAVID W — DirectorSale (S): 20,000 @ $2.74EDGAR
2020-12-294Silver Point Capital L.P. — 10% owner
O'Shea Robert J — 10% owner
MULE EDWARD A — 10% owner
Purchase (P): 128,000 @ $2.65 · Purchase (P): 235,000 @ $2.70 · Purchase (P): 268,600 @ $2.69EDGAR
2020-12-234Silver Point Capital L.P. — 10% owner
O'Shea Robert J — 10% owner
MULE EDWARD A — 10% owner
Purchase (P): 230,000 @ $2.63 · Purchase (P): 850,000 @ $2.59 · Purchase (P): 485,000 @ $2.60EDGAR
2020-12-224MCLAUGHLIN JOHN PETER — DirectorSale (S): 50,000 @ $2.62 · Sale (S): 277,934 @ $2.61EDGAR
2020-12-184Silver Point Capital L.P. — 10% owner
O'Shea Robert J — 10% owner
MULE EDWARD A — 10% owner
Purchase (P): 1,350,000 @ $2.58 · Purchase (P): 398,000 @ $2.61EDGAR
2020-12-174Monnet Dominique — President and CEOSale (S): 500,000 @ $2.60EDGAR
2020-12-174Stone Christopher Lewis — VP, Gen. Counsel & SecretarySale (S): 200,000 @ $2.56EDGAR
2020-12-174GRYSKA DAVID W — DirectorSale (S): 75,000 @ $2.68EDGAR
2020-12-154Silver Point Capital L.P. — 10% owner
O'Shea Robert J — 10% owner
MULE EDWARD A — 10% owner
Purchase (P): 450,000 @ $2.45 · Purchase (P): 640,000 @ $2.62 · Purchase (P): 1,000,000 @ $2.59EDGAR
2020-12-094GRYSKA DAVID W — DirectorOption exercise (M): 66,050 @ $1.64 · Option exercise (M): 66,050 (derivative) @ $1.64EDGAR
2020-12-044Stone Christopher Lewis — VP, Gen. Counsel & SecretaryDisposition to issuer (D): 11,544 @ $0EDGAR
2020-12-044GRYSKA DAVID W — DirectorSale (S): 75,000 @ $2.52EDGAR
2020-11-244O'Farrell Elizabeth G. — DirectorSale (S): 25,826 @ $2.44EDGAR
2020-11-244GRYSKA DAVID W — DirectorSale (S): 50,000 @ $2.43EDGAR
2020-11-204O'Farrell Elizabeth G. — DirectorSale (S): 63,291 @ $2.38EDGAR
2020-11-204Bazaar Alan Lee — DirectorOption exercise (M): 37,080 @ $1.71 · Tax withholding (F): 26,642 @ $2.38 · Sale (S): 33,435 @ $2.42 · Option exercise (M): 37,080 (derivative) @ $1.71EDGAR
2020-11-204GRYSKA DAVID W — DirectorOption exercise (M): 60,000 @ $1.64 · Option exercise (M): 60,000 (derivative) @ $1.64EDGAR
2020-11-194GRYSKA DAVID W — DirectorSale (S): 100,000 @ $2.40 · Sale (S): 50,000 @ $2.39EDGAR
2020-08-244Hernday Natasha — DirectorGrant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63EDGAR
2020-08-244O'Farrell Elizabeth G. — DirectorGrant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63EDGAR
2020-08-244Bazaar Alan Lee — DirectorGrant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63EDGAR
2020-08-244MCLAUGHLIN JOHN PETER — DirectorGrant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63EDGAR
2020-08-244GRYSKA DAVID W — DirectorGrant/award (A): 25,826 @ $0 · Grant/award (A): 118,671 (derivative) @ $3.63EDGAR

Recent 8-K events — PDL BIOPHARMA, INC.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2020-12-148-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2020-12-088-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2020-11-138-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2020-10-078-K2.01 — Completion of Acquisition or Disposition of Assets
9.01 — Financial Statements and Exhibits
EDGAR
2020-10-028-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2020-09-108-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2020-09-108-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2020-09-098-K2.01 — Completion of Acquisition or Disposition of Assets
9.01 — Financial Statements and Exhibits
EDGAR
2020-09-018-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
2020-08-318-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=PDLI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs